Teva Pharma (TEVA) Tops Q1 EPS by 11c

Teva Pharma (NYSE: TEVA) reported Q1 EPS of $1.36, $0.11 better than the analyst estimate of $1.25. Revenue for the quarter came in at $5 billion versus the consensus estimate of $4.84 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• UBS Reiterates Buy Rating on General Motors (GM) as Defense Opportunity in Focus
• Morgan Stanley Starts Adani Enterprises Ltd. (ADE:IN) at Overweight